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Abstract
Background: Tumors frequently exhibit loss of tumor suppressor genes or allelic gains of activated oncogenes. A significant
proportion of cancer susceptibility loci in the mouse show somatic losses or gains consistent with the presence of a tumor
susceptibility or resistance allele. Thus, allele-specific somatic gains or losses at loci may demarcate the presence of
resistance or susceptibility alleles. The goal of this study was to determine if previously mapped susceptibility loci for
colorectal cancer show evidence of allele-specific somatic events in colon tumors.
Methods: We performed quantitative genotyping of 16 single nucleotide polymorphisms (SNPs) showing statistically
significant association with colorectal cancer in published genome-wide association studies (GWAS). We genotyped 194
paired normal and colorectal tumor DNA samples and 296 paired validation samples to investigate these SNPs for allele-
specific somatic gains and losses. We combined analysis of our data with published data for seven of these SNPs.
Results: No statistically significant evidence for allele-specific somatic selection was observed for the tested polymorphisms
in the discovery set. The rs6983267 variant, which has shown preferential loss of the non-risk T allele and relative gain of the
risk G allele in previous studies, favored relative gain of the G allele in the combined discovery and validation samples
(corrected p-value=0.03). When we combined our data with published allele-specific imbalance data for this SNP, the G
allele of rs6983267 showed statistically significant evidence of relative retention (p-value=2.06610
24).
Conclusions: Our results suggest that the majority of variants identified as colon cancer susceptibility alleles through GWAS
do not exhibit somatic allele-specific imbalance in colon tumors. Our data confirm previously published results showing
allele-specific imbalance for rs6983267. These results indicate that allele-specific imbalance of cancer susceptibility alleles
may not be a common phenomenon in colon cancer.
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Introduction
Tumor suppressor genes and oncogenes have long been
recognized to show copy number losses and gains in tumors,
respectively [1,2]. Classically, the wild-type allele of tumor
suppressor genes is lost in tumors whereas the mutated or non-
functional allele shows selective retention. Likewise, an activated
mutation or activated copy of an oncogene is frequently selected
for gain or amplification in tumors. Previous studies using mouse
models show evidence that a subset of susceptibility loci for skin
and colon cancer demonstrate strain-specific gains or losses
consistent with these loci housing tumor promoting alleles or
tumor suppressing alleles [3,4]. For example, PTPRJ, a gene
originally identified as a candidate tumor suppressor mapping to
the mouse Scc1 locus, was shown to preferentially lose a suspected
resistance allele in a subset of heterozygous human colorectal
adenocarcinomas showing loss of heterozygosity at PTPRJ [3].
Allele-specific gains of a single nucleotide polymorphism (SNP) in
AURKA, rs2273535, have been observed in multiple studies of
colorectal tumors [5,6]. Preferential allelic gains or losses in
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wide screens looking at individuals with multiple independent
primary tumors [7] and in genomic studies of glioblastoma
samples via the comparison of germline and somatic genotype data
[8].
Several genome-wide association studies have revealed alleles
associated with colorectal cancer (CRC) risk [9–16]. The SNP
rs6983267 on 8q24 has been associated with both colorectal and
prostate cancer risk at a genome-wide significance level [9,17,18].
Allele-specific copy number analyses showed that the G allele (the
putative risk allele) of this variant shows preferential gains in colon
tumors and myeloid leukemia [19–21]. To our knowledge, no
other SNPs from published GWAS literature have definitively and
reproducibly shown allele-specific imbalance in colorectal tumors,
although individual studies have described allelic imbalance in
CRC for other loci [7,22]. In the present study, we performed
quantitative genotyping of 16 statistically significant variants from
published GWAS (including rs6983267) in paired normal and
colorectal tumor DNA. The goal of this study was to investigate
these SNPs for somatic gain of the susceptibility allele or loss of the
resistance allele using allelic imbalance analyses.
Methods
Human Samples
Ethics statement. This study was approved by The Ohio
State University (OSU) Institutional Review Board. All study
participants provided written informed consent for use of their
tissues in research.
Discovery Set. Paired normal and formalin-fixed paraffin-
embedded (FFPE) tumor tissue blocks were obtained through the
OSU Human Tissue Research Network and the Midwest
Cooperative Human Tissue Network. Tumors that exhibited
microsatellite stability and/or stained positively for the Lynch
syndrome proteins MSH2, MLH1, PMS2, and MSH6 by
immunohistochemistry (IHC) were prioritized for inclusion in
the study. When microsatellite or IHC data were unavailable,
tumors that showed characteristics suggestive of Lynch syndrome
such as right-sided location, poor differentiation, and a high
percentage of mucin were excluded [23]. After selection,
confirmation of diagnosis and DNA extraction, 194 histologically
normal/tumor DNA pairs were available for study.
Validation Set. A validation set of 296 paired non-tumor/
tumor DNA samples were obtained from two existing study
collections. Samples from 196 individuals were acquired from a
population-based study cohort of incident colon cancer diagnosed
in the metropolitan Columbus area [24,25]. Blood DNA was
available for all cases. An additional 100 fresh frozen paired
normal and tumor tissue samples were obtained through the
Cooperative Human Tissue Network at The Ohio State Univer-
sity Medical Center. Specimens were snap-frozen shortly after
surgery and received anonymously along with a full pathology
report. The 296 CRC cases were all classified as likely to be
microsatellite stable, the set of 196 samples was stable by
microsatellite instability testing, and the 100 fresh frozen tumors
all showed intact mismatch repair proteins by immunohistochem-
istry staining.
DNA Extraction
Test Set. Hematoxylin and eosin stains from normal and
tumor FFPE sections were evaluated by a pathologist to confirm
diagnosis and to mark tissues for coring. Tissue cores of 1.6 mm
diameter were prepared from regions consisting of 70% or more
tumor cells for collection of tumor DNA, or from regions with
normal histology for isolation of normal (non-tumor) DNA.
Genomic DNA was extracted from tissue cores as previously
described [26] and quantified with a Nanodrop-1000 spectropho-
tometer. The majority of DNAs were of good quality as indicated
by A260/A280 ratios greater than 1.8.
Validation Set. Tumor DNAs from the Columbus-metro-
politan area study were isolated as described [26]. Normal DNAs
from these individuals were isolated from blood samples in the
OSU Human Genetics Sample Bank by standard protocols. DNAs
from the 100 paired normal/tumor DNA samples from the
Cooperative Human Tissue Network were isolated from the fresh
frozen tissue by the same extraction protocol used for the test set
samples. Normal DNAs from the three sources (FFPE, blood, and
fresh frozen tissue) exhibited similar frequencies of heterozygosity
and similar A260/A280 ratios, suggesting comparable DNA
quality across sample sources.
Inclusion of SNPs for Study
To test our hypothesis that CRC susceptibility loci would show
allele-specific somatic events in tumors, we searched the recent
literature to identify variants showing evidence of CRC risk from
GWA studies [9,10,13–15,27–32]. Seventeen SNPs (rs10411210,
rs10936599, rs11169552, rs16892766, rs3802842, rs4444235,
rs4779584, rs4925386, rs4939827, rs6687758, rs6691170,
rs6983267, rs7014346, rs7136702, rs719725, rs961253,
rs9929218) meeting or approaching genome-wide significance (p-
value,10
27) for CRC risk in published GWA studies were chosen
for analysis of allele-specific imbalance in the initial discovery set of
tumor/normal DNA pairs (Table 1). Other inclusion criteria for
study included identification in Caucasian populations and a
sufficiently high documented minor allele frequency (MAF.20%)
for identification of enough heterozygotes for statistical power.
The SNP rs16892766 was the only exception to this criterion, as it
has a documented MAF of 7%. rs4925386 was eliminated post-
genotyping of the original sample set due to a failure rate greater
than 15%.
Quantitative Genotyping
Multiplexed primers for PCR amplification and allele-specific
single base extension reactions were designed using the Seque-
nomH MassARRAY Assay Design 3.1 software and are available
upon request. Mass spectrometry-based genotyping of 20 ng
paired tumor and normal DNA was performed using SequenomH
MassARRAY iPlex Gold (Sequenom Inc., San Diego, CA, USA)
according to the manufacturer’s protocol. Each 384-well Seque-
nomH plate included four negative template controls (dH2O), two
samples tested in duplicate, and four positive control DNAs.
Verification of Genotyping Technique
To validate the use of SequenomH quantitative genotyping for
its sensitivity for identification of allelic imbalance, we generated
natural log-transformed N-ratios (N-ratio=normal allele 1 peak
area/normal allele 2 peak area) for DNA mixtures of known
homozygote DNA samples representing 0, 20, 40, 50, 60, 80, and
100% allelic contributions. We did not have appropriate
homozygous DNAs for three of the SNPs so these were not
evaluated. The majority of slopes and R-values for these were very
close to standard curves for ‘‘perfect data’’ suggesting a high
degree of sensitivity for our method of detecting allelic deviations
from 50% (Figure S1).
Allele-Specific Imbalance in Colon Cancer
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The SequenomH MassARRAY iPLEX software quantifies the
area under each of the allele peaks and assigns either a
heterozygous or homozygous call to the SNP by calculating the
ratio of the peak areas for the two alleles. As described previously
[7], for all SNPs tested we scored preferential allelic imbalance by
calculating the R-ratio for each DNA pair. We defined the R-ratio
as the ratio of the two allele peak areas in the normal DNA divided
by the ratio of the two allele peak areas in the paired tumor DNA
(R-ratio=Normal
(allele 1/allele 2)/Tumor
(allele 1/allele 2)). Samples
were scored as having imbalance, defined as the loss of either the
first or second allele in the tumor sample, if the R-ratio was greater
than 1.5 or less than 0.67, respectively. The R-ratio thresholds
used to determine imbalance have been described previously
[33,34]. A chi-squared test (df=1) was used to assess the observed
imbalances for statistically significant deviation from the expected
50:50 distribution of allele imbalances. In cases in which a tumor
was heterozygous for a SNP by genotyping but the paired normal
sample failed to genotype, an average of the two normal alleles for
heterozygous normal samples at that SNP was used in place of the
failed normal sample to calculate an R-ratio. SNPs with p-
value,0.10 were considered suggestive of preferential allelic
imbalance and were therefore subjected to testing in the validation
sample set to rule out false positives. Bonferroni correction was
used to adjust for the number of statistical tests. In addition to
qualitative determination of imbalance, we generated box plots of
the distribution of R-ratios for each SNP for samples showing
relative loss of allele 1, relative loss of allele 2, and no imbalance
(Figure S2). Samples were excluded from the plots if they had an
R-ratio of greater than 10 or if an R-ratio could not be calculated
because one of the two alleles in the tumor sample had an allele
peak area value of 0.
Validation Studies
Following statistical analysis of allele-specific imbalance in the
discovery sample set, three variants with p-values,0.1
(rs16892766, rs6983267 and rs7136702) were genotyped by
SequenomH MassARRAY iPlex Gold in a replication sample set
of 296 paired normal/tumor DNAs. The same quantitative
genotyping protocol and statistical analyses used for the discovery
sample set were employed with the validation sample set.
Bonferroni correction was used to adjust for the number of
statistical tests (n=3).
Compilation of Allele-Specific Imbalance Data from
Multiple Studies
Allele-specific imbalance analyses have previously been per-
formed on seven of the GWAS SNPs tested in the present study
[19,35]. These studies employed manual measurement of
sequencing chromatogram peaks for tumor and normal DNAs
to calculate R-ratios. Both published studies utilized R-ratio cutoff
values of ,0.60 and .1.67 for allele-specific imbalance analysis.
For both previously published studies, tumor DNA was isolated
from fresh frozen colon tumors, and blood was used as the source
of normal DNA [19,35]. In order to test the seven variants that
overlapped with our study, we combined the data from the
published studies with our allele-specific imbalance results for
rs6983267, rs961253, rs3802842, rs10411210, rs4444235,
rs4779584, and rs9929218. We combined our numbers of relative
allelic losses with the numbers from the published studies and
Table 1. CRC risk-associated GWAS SNPs assessed for allele-specific imbalance in the present study.
SNP Position
* Gene(s)/Locus Genotype dbSNP MAF
{ GWAS Reference(s) OR (95% CI)
1 P-value
{
rs10411210 chr19:33,532,300 RHPN2 CT T=0.21 [10] 0.87 (0.83–0.91) 4.6610
29
rs10936599 chr3:169,492,101 MYNN synonymous coding CT T=0.30 [15] 0.93 (0.91–0.96) 3.39610
28
rs11169552 chr12:51,155,663
‘ ATF1, DIP2B CT T=0.24 [15] 0.92 (0.90–0.95) 1.89610
210
rs16892766 chr8:117,630,683 EIF3H AC C=0.07 [14,32] 1.43 (1.13–1.82) 3.3610
218
rs3802842 chr11:111,171,709 C11orf93 AC C=0.31 [13,32] 1.11 (1.08–1.15) 5.8610
210
rs4444235 chr14:54,410,919 BMP4 TC C=0.44 [10,32] 1.11 (1.08–1.15) 8.1610
210
rs4779584 chr15:32,994,756 SCG5, GREM1 CT T=0.46 [14,32] 1.70 (1.35–2.14) 4.7610
27
rs4925386 chr20:60,921,044 LAMA5 CT T=0.41 [15] 0.93 (0.91–0.95) 1.89610
210
rs4939827 chr18:46,453,463 SMAD7 CT T=0.38 [27,14,13,32] 0.85 (0.81–0.89) 1.0610
212
rs6687758 chr1:222,164,948
# Intergenic AG G=0.22 [15] 1.09 (1.06–1.12) 2.27610
29
rs6691170 chr1:222,045,446
# Intergenic GT T=0.26 [15] 1.06 (1.03–1.09) 9.55610
210
rs6983267 chr8:128,413,305
n Intergenic GT T=0.44 [9,28,14,31,32] 1.21 (1.15–1.27) 1.27610
214
rs7014346 chr8:128,424,792
n Intergenic GA A=0.33 [13] 1.19 (1.15–1.23) 8.6610
226
rs7136702 chr12:50,880,216
‘ LARP4, DIP2B CT T=0.46 [15] 1.06 (1.04–1.08) 4.02610
28
rs719725 chr9:6,365,683 Intergenic AC C=0.33 [29,28,30] 1.13 (NA) 4.98610
25
rs961253 chr20:6,404,281 BMP2 CA A=0.29 [10,32] 1.12 (1.08–1.16) 2.0610
210
rs9929218 chr16:68,820,946 CDH1 GA A=0.25 [10,32] 0.91 (0.89–0.94) 1.2610
28
*Position by UCSC Genome Browser (Human Feb. 2009 GRCh37/hg19 Assembly).
{MAF=Minor Allele Frequency, as listed on NCBI dbSNP.
1Odds Ratio from first listed GWAS reference (95% confidence interval). NA=not available.
{P-value from first listed GWAS reference.
‘SNP positions in modest linkage disequilibrium (D9=0.76, ref. 15).
#SNP positions in modest linkage disequilibrium (D9=0.71, ref. 15).
nSNP positions in high linkage disequilibrium (D9=0.99, ref. 9).
doi:10.1371/journal.pone.0037672.t001
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determine the statistical significance of the combined imbalances.
Correlation Analysis of Allelic Imbalances and Age, Sex,
and Tumor Stage
For each SNP successfully assessed for allelic imbalance, we
investigated the association between the presence of allelic
imbalance and age of diagnosis, sex, and tumor stage of the
patient. Chi-squared statistical test was used to detect association
between allelic imbalance and sex. Fisher exact statistical test was
used to detect association between allelic imbalance and tumor
stage. For tumor stage, we classified tumors as TNM stage I–IV
according to available tumor size, nodal spread, and metastasis
information. The sample t-test was used to compare the average
age of patients whose tumors showed allelic imbalance to that of
patients whose tumors maintained heterozygosity. Correlations
with corrected p-values,0.05 were deemed statistically significant.
Results
Discovery Set Genotyping
To determine if any of the 17 CRC-associated SNPs show
evidence of allele-specific imbalance, we genotyped them in 194
normal/tumor DNA pairs. All but one SNP, rs4925386, were
successfully genotyped in greater than 85% of samples in the
discovery set. Due to a high rate of genotyping failures (24%),
rs4925386 was excluded from further analysis. The number of
heterozygous normal DNAs identified for each SNP (for which the
paired tumor DNA was also successfully genotyped) ranged from
27 to 84 of the 194 samples (14–43%; Table 2). The frequency of
overall relative allele loss (for both risk and non-risk alleles
combined) ranged from 2% to 44%. While none of the SNPs
reached statistical significance for allele-specific imbalance at
a=0.05, three SNPs (rs16892766, rs6983267, rs7136702) showed
a trend for allele-specific imbalance (p-values,0.10) prior to
Bonferroni correction for multiple comparison (n=16). The SNP
rs6983267 showed higher frequencies of relative loss of the non-
risk T allele compared to the risk G allele. Interestingly,
rs16892766 and rs7136702 both demonstrated higher frequencies
of relative loss of the risk allele compared to the non-risk allele in
the discovery set tumors. The variants rs16892766, rs6983267 and
rs7136702 were prioritized for validation in a second set of
samples. In addition to qualitatively scoring the SNPs as showing
imbalance or no imbalance, the distribution of R-ratios for relative
loss of the risk allele, relative loss of the non-risk allele and no
imbalance were graphed as boxplots for each SNP (Figure S2).
Samples for which the R-ratio was greater than 10 or for which
the R-ratio could not be calculated were excluded from the plots.
Validation Set Genotyping
The SNPs rs16892766, rs6983267 and rs7136702, which all
showed evidence of allele-specific imbalance in the original
discovery set, were further tested in the validation sample set of
296 normal/tumor DNA pairs. As with the test set, these three
SNPs successfully genotyped in greater than 85% of the validation
samples. With 22% of the validation set heterozygotes showing
relative loss of an allele, rs6983267 showed a frequency of overall
relative allele loss lower than that observed in the original test set
(30%; Table 3). A lower frequency of heterozygous samples in the
validation set showed relative loss of an allele of rs7136702 (11%)
compared to the test set (23%; Table 3). Similarly, a lower
frequency of allelic loss of rs16892766 was observed in the
validation sample set (16%) compared to the original test set (26%;
Table 3). rs6983267 again showed a tendency towards statistically
significant preferential allelic imbalance (p-value=0.06), favoring
relative loss of the non-risk T allele and relative retention of the
risk G allele in the validation sample set. However, neither
rs7136702 nor rs16892766 showed a statistically significant
tendency towards preferential allelic imbalance in the validation
sample set (p-values=0.59 and 1.00, respectively).
Combined Genotyping Results from Discovery and
Validation Sample Sets
When the test set and validation set genotypes were combined,
48 of 192 heterozygous samples (25%) showed relative loss of an
allele of rs6983267 (Table 3). For the SNP rs7136702, 31 of 208
combined heterozygotes showed relative loss of either allele (15%).
When genotypes from the test set and validation set were
combined for rs16892766, 13 of 65 heterozygotes (20%) showed
allelic loss. By pooled analysis rs6983267 showed strong statistical
evidence of preferential allelic imbalance (p-value=0.01). After
Bonferroni correction for multiple comparisons testing (n=3),
rs6983267 maintained a statistically significant adjusted p-value of
0.03. In contrast, both rs16892766 and rs7136702 failed to show
any tendency towards significant allele-specific imbalance by
combined analysis (unadjusted p-values=0.17 and 0.37, respec-
tively).
Compilation of Allelic Imbalance Data from Multiple
Studies
Because others have published allele-specific imbalance data on
seven variants from our study [19,35], we decided to perform
combined analysis of the present study and the previously
published studies to increase the power of identifying SNPs
demonstrating allele-specific imbalance. When the imbalances
observed in our samples at the SNPs rs6983267, rs961253,
rs3802842, rs10411210, rs4444235, rs4779584, and rs9929218
were combined with those published previously [19,35], we
observed a highly significant relative loss of the non-risk T allele of
rs6983267 (p-value=2.94610
25). After Bonferroni correction
(n=7), the preferential relative loss of the T allele of rs6983267
maintained a highly significant p-value of 2.06610
24. None of the
other variants showed statistically significant evidence of prefer-
ential allelic imbalance (Table 4).
Correlation Analysis of Allelic Imbalances and Age, Sex,
and Tumor Stage
To test whether samples showing allelic imbalance for the
GWAS SNPs had different clinical characteristics compared to
samples not showing imbalance, we performed a correlation
analysis of imbalance with age, sex and tumor stage using data
from our discovery sample set. The presence of allelic imbalance
was significantly associated with tumor stage for rs719725
(unadjusted p-value=0.0098), and significantly associated with
younger age for rs7014346 (unadjusted p-value=0.033). However,
after adjusting for multiple comparisons (n=16), there was no
significant association between the presence of allelic imbalance
and age, sex, and tumor stage (adjusted p-values.0.05) for any of
the tested SNPs.
Discussion
In this study, we investigated 16 SNPs previously associated
with CRC risk for allele-specific imbalance using the SequenomH
MassARRAY iPLEX Gold genotyping platform. While 15 of the
16 tested SNPs did not show statistically significant evidence (p-
value,0.05) of preferential allelic imbalance in our discovery
Allele-Specific Imbalance in Colon Cancer
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statistically significant somatic loss of the non-risk T allele and
retention of the risk G allele in both the original discovery set and
the validation sample set (p-values=0.07 and 0.06, respectively;
Tables 2 and 3). This is consistent with previously published
reports [19,20]. Interestingly, despite being in high linkage
disequilibrium with rs6983267 at 8q24 (D9=0.99) [9,13],
rs7014346 did not show evidence of preferential allelic imbalance
(p-value=0.53) in the discovery sample set. In the largest previous
study to assess allelic imbalance for rs6983267, 466 heterozygous
Table 2. Analysis of allele-specific imbalance in discovery sample set.
SNP Risk Allele Non-risk Allele Risk Allele Lost
* Non-risk Allele Lost
{ Total Imbalance
1 Unadjusted P-value
{
rs16892766 C A 6 (22%) 1 (4%) 7/27 (26%) 0.06
rs6983267 G T 6 (9%) 14 (21%) 20/67 (30%) 0.07
rs7136702 T C 12 (16%) 5 (7%) 17/75 (23%) 0.09
rs10936599 C T 6 (12%) 2 (4%) 8/49 (16%) 0.16
rs3802842 C A 9 (12%) 4 (5%) 13/75 (17%) 0.17
rs961253 A C 11 (15%) 6 (8%) 17/71 (24%) 0.23
rs6687758 G A 8 (15%) 4 (7%) 12/55 (22%) 0.25
rs4779584 T C 9 (17%) 14 (26%) 23/53 (43%) 0.30
rs4939827 T C 19 (24%) 15 (19%) 34/78 (44%) 0.49
rs7014346 A G 6 (7%) 4 (5%) 10/82 (12%) 0.53
rs9929218 G A 2 (3%) 1 (2%) 3/62 (5%) 0.56
rs10411210 C T 4 (11%) 3 (9%) 7/35 (20%) 0.71
rs4444235 C T 8 (10%) 7 (9%) 15/81 (19%) 0.80
rs719725 A C 8 (12%) 9 (14%) 17/65 (26%) 0.81
rs6691170 T G 5 (6%) 5 (6%) 10/79 (13%) 1.00
rs11169552 C T 1 (1%) 1 (1%) 2/84 (2%) 1.00
*Risk Allele Lost refers to relative loss of the risk allele compared to the non-risk allele. Number in parentheses indicates percentage of total heterozygous samples
showing relative loss of risk allele.
{Non-risk Allele Lost refers to relative loss of the non-risk allele compared to the risk allele. Number in parentheses indicates percentage of total heterozygous samples
showing relative loss of non-risk allele.
1Total number of tumors with imbalance/total heterozygous samples (% of heterozygotes showing imbalance).
{Chi-squared statistical test, df=1. Unadjusted for multiple comparisons.
doi:10.1371/journal.pone.0037672.t002
Table 3. Analysis of allele-specific imbalance in discovery, validation, and combined sample sets.
SNP Sample Set Risk Allele Non-risk Allele
Risk Allele
Lost
*
Non-risk Allele
Lost
{ Total Imbalance
1 P-value
{
Adjusted
P-value
‘
rs7136702
Discovery T C 12 (16%) 5 (7%) 17/75 (23%) 0.09 1.00
Validation T C 6 (5%) 8 (6%) 14/133 (11%) 0.59 1.00
Combined T C 18 (9%) 13 (6%) 31/208 (15%) 0.37 1.00
rs16892766
Discovery C A 6 (22%) 1 (4%) 7/27 (26%) 0.06 0.96
Validation C A 3 (8%) 3 (8%) 6/38 (16%) 1.00 1.00
Combined C A 9 (14%) 4 (6%) 13/65 (20%) 0.17 0.51
rs6983267
Discovery G T 6 (9%) 14 (21%) 20/67 (30%) 0.07 1.00
Validation G T 9 (7%) 19 (15%) 28/125 (22%) 0.06 0.18
Combined G T 15 (8%) 33 (17%) 48/192 (25%) 0.01 0.03
*Risk Allele Lost refers to relative loss of risk allele compared to non-risk allele. Number in parentheses indicates percentage of total heterozygous samples showing
relative loss of risk allele.
{Non-risk Allele Lost refers to relative loss of non-risk allele compared to risk allele. Number in parentheses indicates percentage of total heterozygous samples showing
relative loss of non-risk allele.
1Total number of tumors with imbalance/total heterozygous samples (% of heterozygotes showing imbalance).
{Chi-squared statistical test, df=1.
‘Bonferroni correction for 16 multiple comparisons (original) or 3 multiple comparisons (validation, combined).
doi:10.1371/journal.pone.0037672.t003
Allele-Specific Imbalance in Colon Cancer
PLoS ONE | www.plosone.org 5 May 2012 | Volume 7 | Issue 5 | e37672tumors from Finnish CRC patients were successfully evaluated
and 101 of these heterozygous samples (22%) showed allelic
imbalance [19]. Among these 101 samples, there were significantly
(p-value=0.0007) more tumors showing relative loss of the T allele
(66% of tumors) versus relative loss of the G allele (34% of tumors).
From our discovery and validation sets combined, we evaluated
tumors from individuals heterozygous for the rs6983267 variant,
and 48 (25%) of these heterozygotes showed allelic imbalance. We
observed a nearly identical percentage of tumors showing relative
loss of the T allele (33 of 48; 69%) versus the G allele (15 of 48;
31%). This was significant even after adjusting for multiple
comparisons testing (p-value=0.03; Table 3). Thus, our data
support the observation of preferential allelic imbalance for
rs6983267 and validate our experimental method. Furthermore,
when we combined our data with that of Tuupanen et al. [19], we
observed a highly significant relative loss of the T allele and
relative gain of the G allele that withstood multiple comparisons
testing (p-value=2.06610
24; Table 4). Importantly, the finding
that the risk G allele may be selectively retained or gained in
colorectal tumors is consistent with a study showing that the G
allele of rs6983267 demonstrates enhanced binding of the Wnt-
regulated transcription factor TCF4, perhaps leading to increased
responsiveness to Wnt signaling in individuals carrying the G risk
allele [20]. Additionally, these data confirm that allele-specific
imbalance does occur for CRC susceptibility loci, albeit at a low
frequency.
In another recent study, somatic allelic imbalance was
investigated at seven low-penetrance CRC susceptibility loci
[35]. The loci-tagging SNPs rs4779584, rs3802842, rs4444235,
rs9929218, rs10411210, and rs961253 that were genotyped in our
study were among the seven variants tested for allele specific
imbalance in the study by Niittyma ¨ki et al. [35]. While none of
these SNPs showed evidence of preferential allelic imbalance in
the combined analysis with our data, one of these SNPs (rs961253)
demonstrated similar allelic imbalance trends as those observed in
our discovery sample set, with rs961253 showing more frequent
relative loss of the A allele in both studies (Table 4). Rates of
heterozygosity and imbalance were very similar between the two
studies with the exception of our study showing a higher degree of
allelic imbalance for rs4779584.A combined analysis of our data
and the data from Niittyma ¨ki et al. [35] for the six variants in
common did not reveal any SNPs with evidence of allele-specific
imbalance. A caveat to combining data from the present study
with that from published data sets is that the percentage of tumor
cells in the samples as well as genotyping methods and R-value
cutoffs for determining allelic imbalance differ across studies.
Nonetheless, our study reproduces the finding that these six loci-
tagging SNPs show no evidence for preferential allelic imbalance
in predominantly Caucasian study populations.
Although only one of the SNPs tested in the present study
showed strong evidence of preferential allelic imbalance, the other
SNPs may play a role in germline predisposition for CRC
independent of somatic events in the tumor. It has been proposed
that these SNPs influence the development of neoplasms but do
not affect subsequent somatic neoplastic progression [35]. The
functional SNPs at the GWAS-identified loci may influence
neoplastic development by modifying gene expression, methyla-
tion, or splicing patterns in such a way that selection at the DNA
level is not required during tumorigenesis. These SNPs could also
impact non-tumor cells, such as stromal or immune cells to modify
cancer risk, but be independent of the cancer cells themselves.
Once the mechanism by which these variants act to confer risk is
better understood, we may be able to deduce which variants are
more likely to show selection in tumors.
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37672Inherent limitations in our study design could further mask
existing preferential allelic selection. First, it is possible that normal
cells were isolated with tumor cells in the tumor tissue cores from
which DNA was extracted for analysis. Despite initial selection of
regions of the tumor containing 70% or greater tumor cells, some
normal DNA contamination of the tumor DNA sample could bias
the sample towards showing no imbalance. However, our
histological examination of the tissue samples should minimize
the possibility of normal DNA contamination. Similarly, our
histologically normal samples from FFPE colon tissue may not be
normal and may contain similar somatic mutations as the tumor,
which could result in a general ‘‘undercalling’’ of tumors with
imbalance. Whenever possible the normal colon tissue was
collected from sites distant from the tumor. Second, we employed
conservative data inclusion practices by discounting aggressive
genotype calls made by the SequenomH MassARRAY iPLEX
software and by instilling R-ratio cutoffs of .1.5 and ,0.67 for
determination of allelic imbalance. Our rigorous requirements for
inclusion of data may limit detection of borderline significant
allelic imbalance, particularly in tumor samples containing non-
tumor cells. Furthermore, if tumors are heterogeneous for allelic
loss we may not detect imbalances in that sample. Third, our
discovery sample set was limited to 194 normal/tumor DNA pairs
and may have lacked statistical power for detection of preferential
allelic selection in loci showing lower levels of heterozygosity or less
frequent genomic aberration. Based on mouse data showing that
about 40% of susceptibility loci demonstrate preferential allelic
imbalance [4], we did not expect all SNPs identified through
GWA studies to show preferential allelic selection in tumors.
However, our results are surprising in that only one SNP,
rs6983267, showed a trend towards somatic selection in the colon
tumors. These results may indicate differences between species,
differences between colon and skin tumors, or may be the result of
the discussed study limitations.
In conclusion, our results suggest that the majority of variants
identified as colon cancer susceptibility alleles through GWAS do
not exhibit somatic allele-specific imbalance in colon tumors.
However, our data confirm previously published results showing
allele-specific imbalance for rs6983267. These results indicate that
somatic allele-specific imbalance of cancer susceptibility alleles
may not be a common phenomenon in colon cancer, but that for a
small percentage of loci (1 of 16, or 6%, observed in the present
study), somatic selection of specific alleles may be driving
tumorigenesis.
Supporting Information
Figure S1 Standard Curves for SNPs. Standard curves for
13 of the tested GWAS SNPs were generated by mixing control
DNAs known to be homozygous for either allele in different
proportions so as to generate mixtures of 0, 20, 40, 50, 60, 80 and
100% allele 1. DNA mixtures were quantitatively genotyped using
SequenomH MassARRAY iPLEX Gold, and the percentage of
allele 1 was plotted against natural log-transformed N-ratio. The
line of best fit, linear equation in the form ln(N-ratio)=m(% allele
1)+b, and correlation coefficient R
2 are shown for each GWAS
SNP for which the appropriate control homozygote DNA was
available. The expected equation for the ideal standard curve is:
ln(N-ratio)=20.0456(% allele 1)+2.2822.
(DOC)
Figure S2 Box plots of R-ratios. Box plots for each call
relative loss of allele 1, relative loss of allele 2 and no imbalance are
plotted for each of the 16 SNPs genotyped in the discovery sample
set. Average R-ratio is indicated by a white line and the standard
deviation within each group is denoted. Outlier samples are
indicated by a dot except for samples with R-ratios greater than 10
which were removed from the figure.
(DOCX)
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